Bayer AG (BAYRY)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Bayer AG (BAYRY) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 51/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Bayer AG (BAYRY) Gesundheitswesen & Pipeline-Uebersicht
Bayer AG, a life science company established in 1863, operates across pharmaceuticals, consumer health, and crop science, providing prescription drugs, over-the-counter medicines, and agricultural solutions. With a global presence and a focus on innovation, Bayer faces competition from both established pharmaceutical companies and agricultural technology firms.
Investmentthese
Bayer AG presents a complex investment case. With a market capitalization of $43.19 billion, the company's negative P/E ratio of -10.49 and a negative profit margin of -7.9% reflect current challenges. The dividend yield of 0.28% offers modest income. Growth catalysts include potential breakthroughs in oncology and strategic partnerships. However, the company faces risks related to regulatory hurdles, patent expirations, and potential liabilities from its Crop Science segment. Investors should carefully weigh these factors when evaluating Bayer's long-term potential.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $43.19B reflects Bayer's substantial size within the life science industry.
- Gross Margin of 58.8% indicates strong pricing power in its key product segments.
- Negative P/E Ratio of -10.49 suggests current earnings challenges.
- Dividend Yield of 0.28% provides a modest return for investors.
- Beta of 0.93 indicates lower volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diversified business segments across pharmaceuticals, consumer health, and crop science.
- Strong brand reputation and global presence.
- Extensive research and development capabilities.
- Established distribution network and customer relationships.
Schwaechen
- Negative profit margin and P/E ratio.
- Potential liabilities related to Crop Science segment.
- Exposure to regulatory risks and patent expirations.
- Dependence on successful product development and commercialization.
Katalysatoren
- Upcoming: Potential regulatory approvals for new pharmaceutical products in key markets.
- Ongoing: Strategic collaborations with MD Anderson Cancer Center and other research institutions.
- Ongoing: Expansion of digital solutions for agriculture to improve crop yields.
- Upcoming: Launch of new consumer health products targeting specific health needs.
- Ongoing: Cost-cutting initiatives to improve profitability and efficiency.
Risiken
- Ongoing: Potential liabilities related to the Crop Science segment and glyphosate-related lawsuits.
- Potential: Regulatory hurdles and delays in obtaining approvals for new products.
- Ongoing: Patent expirations and generic competition for key pharmaceutical products.
- Potential: Economic downturns and market volatility affecting demand for products.
- Potential: Currency fluctuations impacting revenue and profitability.
Wachstumschancen
- Expansion in Oncology: Bayer has ongoing collaborations with MD Anderson Cancer Center to develop oncology drugs. The global oncology market is projected to reach $350 billion by 2030, presenting a significant growth opportunity for Bayer. Successful development and commercialization of new cancer therapies could drive substantial revenue growth.
- Strategic Partnerships in Pharmaceuticals: Bayer's research and license agreement with Dewpoint Therapeutics focuses on developing treatments for cardiovascular and gynecological diseases. The cardiovascular disease market is expected to reach $250 billion by 2028. Successful development of new therapies in this area could significantly boost Bayer's pharmaceutical revenues.
- Digital Solutions in Agriculture: Bayer is investing in digital solutions for agriculture to improve crop yields and sustainability. The digital agriculture market is projected to reach $12 billion by 2027. Bayer's digital platforms can provide farmers with data-driven insights, optimizing resource utilization and increasing productivity.
- Growth in Consumer Health: The consumer health market is expanding due to increasing self-care trends and an aging population. Bayer's focus on over-the-counter medicines, medical products, and nutritional supplements positions it well to capitalize on this growth. The global consumer health market is expected to reach $350 billion by 2025.
- Innovation in Crop Protection: Bayer continues to innovate in crop protection products, including chemical and biological solutions. The global crop protection market is projected to reach $80 billion by 2027. Bayer's focus on sustainable agriculture and integrated pest management can drive growth in this segment.
Chancen
- Expansion in oncology and other high-growth therapeutic areas.
- Strategic partnerships and collaborations to drive innovation.
- Growth in digital agriculture and sustainable farming practices.
- Increasing demand for consumer health products and self-care solutions.
Risiken
- Intense competition from other life science companies.
- Evolving regulations and increasing scrutiny regarding product safety.
- Economic downturns and market volatility.
- Patent expirations and generic competition.
Wettbewerbsvorteile
- Strong brand recognition and reputation in the life science industry.
- Extensive patent portfolio protecting key products and technologies.
- Global distribution network and established relationships with customers.
- Significant investment in research and development, driving innovation.
Ueber BAYRY
Founded in 1863 in Leverkusen, Germany, Bayer Aktiengesellschaft has evolved from a dyestuff factory into a global life science powerhouse. The company operates through three primary segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment develops and markets prescription products, focusing on cardiology, women's health, oncology, hematology, and ophthalmology, along with diagnostic imaging equipment and cell and gene therapy. The Consumer Health segment offers a wide range of nonprescription medicines, medical products, and self-care solutions in areas like dermatology, nutritional supplements, pain relief, digestive health, and allergy. The Crop Science segment provides chemical and biological crop protection products, seeds, and digital solutions for agriculture, supporting farmers in improving yields and sustainability. Bayer distributes its products through various channels, including wholesalers, pharmacies, supermarkets, online retailers, and directly to farmers. Through strategic collaborations with institutions like MD Anderson Cancer Center and the University of Oxford, Bayer continues to innovate and expand its product portfolio.
Was das Unternehmen tut
- Develop and market prescription drugs for various therapeutic areas.
- Offer over-the-counter medicines and self-care solutions.
- Provide crop protection products, seeds, and digital solutions for agriculture.
- Develop diagnostic imaging equipment and contrast agents.
- Engage in cell and gene therapy research and development.
- Offer products for cardiology and women's health care.
- Provide solutions for oncology, hematology, and ophthalmology.
Geschaeftsmodell
- Develop, manufacture, and market pharmaceutical products.
- Produce and distribute consumer health products through various channels.
- Offer crop science solutions to farmers and agricultural businesses.
- Generate revenue through product sales, licensing agreements, and collaborations.
Branchenkontext
Bayer operates in the highly competitive life science industry, encompassing pharmaceuticals, consumer health, and crop science. The pharmaceutical sector is characterized by intense research and development, stringent regulatory requirements, and patent protection. The consumer health market is driven by increasing self-care trends and an aging population. The crop science industry faces challenges related to sustainability, climate change, and food security. Bayer competes with major players like ALPMF, ALPMY, FSNUF, GIKLY, and JDHIF, all vying for market share through innovation and strategic partnerships. The industry is subject to evolving regulations and increasing scrutiny regarding environmental impact and product safety.
Wichtige Kunden
- Patients who use prescription and over-the-counter medications.
- Consumers who purchase self-care products and nutritional supplements.
- Farmers and agricultural businesses who use crop protection products and seeds.
- Hospitals and healthcare providers who use diagnostic imaging equipment.
Finanzdaten
Chart & Info
Bayer AG (BAYRY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
Yahoo! Finance: BAYRY News · 26. März 2026
-
Bayer: Turnaround Is Underway - Don't Miss It
seekingalpha.com · 26. März 2026
-
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
businesswire.com · 26. März 2026
-
Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Grows By 178.9%
defenseworld.net · 25. März 2026
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BAYRY.
Kursziele
Wall-Street-Kurszielanalyse fuer BAYRY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von BAYRY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Aktuelle Nachrichten
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
Bayer: Turnaround Is Underway - Don't Miss It
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Grows By 178.9%
Fuehrung: William N. Anderson
Unknown
Information on William N. Anderson's background is not available in the provided data. Without additional context, it is impossible to provide details on his career history, education, or previous roles.
Erfolgsbilanz: Information on William N. Anderson's track record is not available in the provided data. Without additional context, it is impossible to provide details on his key achievements, strategic decisions, or company milestones under his leadership.
Bayer AG ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) like BAYRY represents shares of a foreign company (Bayer AG) held by a U.S. depositary bank. This allows U.S. investors to trade shares of Bayer AG on U.S. exchanges as if they were domestic securities, simplifying the process of investing in foreign companies.
- Heimatmarkt-Ticker: Frankfurt Stock Exchange (BAYR), Germany
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: BAYR
BAYRY OTC-Marktinformationen
The OTC Other tier is the lowest tier of the over-the-counter (OTC) market, indicating that Bayer AG (BAYRY) has chosen not to meet the requirements for higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial disclosure and do not have to adhere to the same listing standards as companies on the NYSE or NASDAQ. This tier is often associated with higher risk and less liquidity compared to listed exchanges.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for wider bid-ask spreads and price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Less regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Bayer AG is a well-established company with a long history.
- The company operates in regulated industries (pharmaceuticals, consumer health, crop science).
- Bayer AG has a global presence and a diverse product portfolio.
- The company is subject to regulatory oversight in its primary markets (e.g., Germany).
- Bayer AG has strategic partnerships with reputable institutions.
Was Anleger ueber Bayer AG (BAYRY) wissen wollen
What are the key factors to evaluate for BAYRY?
Bayer AG (BAYRY) currently holds an AI score of 51/100, indicating moderate score. Key strength: Diversified business segments across pharmaceuticals, consumer health, and crop science.. Primary risk to monitor: Ongoing: Potential liabilities related to the Crop Science segment and glyphosate-related lawsuits.. This is not financial advice.
How frequently does BAYRY data refresh on this page?
BAYRY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BAYRY's recent stock price performance?
Recent price movement in Bayer AG (BAYRY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified business segments across pharmaceuticals, consumer health, and crop science.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BAYRY overvalued or undervalued right now?
Determining whether Bayer AG (BAYRY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BAYRY?
Before investing in Bayer AG (BAYRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BAYRY to a portfolio?
Potential reasons to consider Bayer AG (BAYRY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diversified business segments across pharmaceuticals, consumer health, and crop science.. Additionally: Strong brand reputation and global presence.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of BAYRY?
Yes, most major brokerages offer fractional shares of Bayer AG (BAYRY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BAYRY's earnings and financial reports?
Bayer AG (BAYRY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BAYRY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.